{"id":625938,"date":"2022-11-16T18:42:01","date_gmt":"2022-11-16T18:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=625938"},"modified":"2022-11-16T18:42:01","modified_gmt":"2022-11-16T18:42:01","slug":"acute-kidney-injury-clinical-trials-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-atox-bio-quarkpharmaceuticals-am-pharma-holding-lg-chem-pharming-group-angion","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-kidney-injury-clinical-trials-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-atox-bio-quarkpharmaceuticals-am-pharma-holding-lg-chem-pharming-group-angion_625938.html","title":{"rendered":"Acute Kidney Injury Clinical Trials, Pipeline, Emerging Therapies and Key pharma players involved by DelveInsight | Atox Bio, Quark-Pharmaceuticals, AM Pharma Holding, LG Chem, Pharming Group, Angion"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1668578524.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Acute Kidney Injury Clinical Trials, Pipeline, Emerging Therapies and Key pharma players involved by DelveInsight | Atox Bio, Quark-Pharmaceuticals, AM Pharma Holding, LG Chem, Pharming Group, Angion \" src=\"https:\/\/www.abnewswire.com\/uploads\/1668578524.png\" alt=\"Acute Kidney Injury Clinical Trials, Pipeline, Emerging Therapies and Key pharma players involved by DelveInsight | Atox Bio, Quark-Pharmaceuticals, AM Pharma Holding, LG Chem, Pharming Group, Angion \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Acute Kidney Injury Clinical Trials<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Acute Kidney Injury<\/strong> (AKI), also known as acute renal failure (ARF), is a sudden episode of kidney failure or kidney damage. AKI is characterized by abrupt deterioration in kidney function, manifested by an increase in serum creatinine level with or without reduced urine output.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>Acute Kidney Injury Pipeline<\/strong> Insight, 2022&rdquo; report provides comprehensive insights about <strong>30+ companies and 30+ pipeline drugs<\/strong> in Acute Kidney Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more Acute Kidney Injury pipeline report offerings, click here: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-kidney-injury-aki-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Acute Kidney Injury Pipeline Insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Acute Kidney Injury Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Acute Kidney Injury Pipeline report depicts a robust space with&nbsp;25+&nbsp;active players working to develop&nbsp;25+&nbsp;pipeline therapies for Acute Kidney Injury treatment.&nbsp;<\/li>\n<li>The major Acute Kidney Injury companies include&nbsp;Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, Nephraegis Therapeutics, Vasomune, Unicycive, ABIONYX&nbsp;and others are developing novel drug candidates to improve the&nbsp;Acute Kidney Injury treatment landscape.<\/li>\n<li>Key Acute Kidney Injury pipeline therapies in various stages of development include&nbsp;bRESCAP, ANG-3777, EA-230, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), UMC 119 06, Kidney specific amniotic mesenchymal stem cell therapy, RMC 035, SBI-101, QPI-1002, RMC035, MIB-626, RBT-9, Recombinant human alkaline phosphatase, XRx-101, SUL-138, UNI494, Timbetasin, and others.<\/li>\n<li>In March 2022, at the&nbsp;27th International Conference on Advances in Critical Care Nephrology,&nbsp;AM-Pharma&nbsp;will deliver an overview of the current&nbsp;Phase III REVIVAL study.<\/li>\n<li>In&nbsp;September 2021,&nbsp;AM-Pharma&nbsp;agreed to an exclusive licensing deal with&nbsp;Kyowa Kirin&nbsp;giving&nbsp;Kyowa Kirin&nbsp;the rights to develop and sell&nbsp;ilofotase alfa&nbsp;in Japan.<\/li>\n<li>Angion and Vifor&nbsp;publicly published findings on&nbsp;ANG-3777&nbsp;clinical trials in 2021, including a&nbsp;Phase II CSA-AKI trial&nbsp;and a&nbsp;Phase III DGF trial.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent breakthroughs happening Acute Kidney Injury pipeline landscape in @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-kidney-injury-aki-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Acute Kidney Injury Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>A snapshot of the Acute Kidney Injury Pipeline Drugs mentioned in the report:<\/strong><\/p>\n<table style=\"width: 460px;\" border=\"1\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p><strong>Drugs<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Company<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Phase&nbsp;<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>MoA<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>RoA<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>ANG-3777<\/p>\n<\/td>\n<td>\n<p>Angion Biomedica\/Vifor Pharma<\/p>\n<\/td>\n<td>\n<p>Phase II<\/p>\n<\/td>\n<td>\n<p>Proto oncogene protein c met stimulant<\/p>\n<\/td>\n<td>\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>Ilofotase alfa<\/p>\n<\/td>\n<td>\n<p>AM Pharma<\/p>\n<\/td>\n<td>\n<p>Phase III<\/p>\n<\/td>\n<td>\n<p>Endotoxin inhibitors; Enzyme replacements<\/p>\n<\/td>\n<td>\n<p>NA<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>ASP1128<\/p>\n<\/td>\n<td>\n<p>Astellas Pharma<\/p>\n<\/td>\n<td>\n<p>Phase II<\/p>\n<\/td>\n<td>\n<p>Peroxisome proliferator-activated receptor delta modulators<\/p>\n<\/td>\n<td>\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>Ruconest (Conestat alfa)<\/p>\n<\/td>\n<td>\n<p>Pharming Technologies<\/p>\n<\/td>\n<td>\n<p>Phase II<\/p>\n<\/td>\n<td>\n<p>Complement C1 inhibitor protein replacements; Complement C1r inhibitors; Complement C1s inhibitors<\/p>\n<\/td>\n<td>\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>RMC-035<\/p>\n<\/td>\n<td>\n<p>Guard Therapeutics<\/p>\n<\/td>\n<td>\n<p>Phase II<\/p>\n<\/td>\n<td>\n<p>Alpha 1 microglobulin replacements<\/p>\n<\/td>\n<td>\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>SBI-101<\/p>\n<\/td>\n<td>\n<p>Sentien Biotechnologies<\/p>\n<\/td>\n<td>\n<p>Phase I\/II<\/p>\n<\/td>\n<td>\n<p>Stem cell modulators<\/p>\n<\/td>\n<td>\n<p>Parenteral<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>Timbetasin<\/p>\n<\/td>\n<td>\n<p>RegeneRx Biopharmaceuticals<\/p>\n<\/td>\n<td>\n<p>Preclinical<\/p>\n<\/td>\n<td>\n<p>Actin modulators; Amyloid inhibitors<\/p>\n<\/td>\n<td>\n<p>NA<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the novel and emerging Acute Kidney Injury pipeline therapies @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-kidney-injury-aki-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Acute Kidney Injury Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Acute Kidney Injury report covers around 40+ products under different phases of clinical development like:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report to get detailed information about the recent developments in Acute Kidney Injury treatment landscape: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-kidney-injury-aki-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Acute Kidney Injury Treatment and Medication<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Acute Kidney Injury Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage:&nbsp;<\/strong>Global<\/li>\n<li><strong>Key Acute Kidney Injury Companies: <\/strong>Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Pharming Technologies, and others.<\/li>\n<li><strong>Key Acute Kidney Injury Pipeline Therapies<\/strong>: bRESCAP, ANG-3777, EA-230, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), and others.<\/li>\n<li><strong>Therapeutics Assessment&nbsp;By Mechanism of Action:&nbsp;<\/strong>Alpha 1 microglobulin replacements, Antioxidants, Free radical scavengers, Haemoglobin inhibitors, Decyclizing heme oxygenase inhibitors, Immunomodulators, Virus replication inhibitors, CD28 antigen modulators, Immunomodulators, Cell replacements, RNA interference, Tumour suppressor protein p53 inhibitors<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about the latest FDA approvals of Acute Kidney Injury drugs, click here: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-kidney-injury-aki-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Acute Kidney Injury therapies and drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Acute Kidney Injury: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Acute Kidney Injury &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Acute Kidney Injury Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Teprasiran: Quark-Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">EH 301: Elysium Health<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Centhaquine: Pharmazz<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Preclinical\/Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Timbetasin: RegeneRx Biopharmaceuticals<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Acute Kidney Injury Key Companies<\/p>\n<p style=\"text-align: justify;\">Acute Kidney Injury Key Products<\/p>\n<p style=\"text-align: justify;\">Acute Kidney Injury- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Acute Kidney Injury- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Acute Kidney Injury- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Acute Kidney Injury Analyst Views<\/p>\n<p style=\"text-align: justify;\">Acute Kidney Injury Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=acute-kidney-injury-clinical-trials-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-atox-bio-quarkpharmaceuticals-am-pharma-holding-lg-chem-pharming-group-angion\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=acute-kidney-injury-clinical-trials-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-atox-bio-quarkpharmaceuticals-am-pharma-holding-lg-chem-pharming-group-angion\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Acute Kidney Injury Clinical Trials Acute Kidney Injury (AKI), also known as acute renal failure (ARF), is a sudden episode of kidney failure or kidney damage. AKI is characterized by abrupt deterioration in kidney function, manifested by an increase in &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/acute-kidney-injury-clinical-trials-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-atox-bio-quarkpharmaceuticals-am-pharma-holding-lg-chem-pharming-group-angion_625938.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-625938","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/625938","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=625938"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/625938\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=625938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=625938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=625938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}